Mugilan Poongkunran
Neurology · New Orleans, LANPI 1992169858
Payments from drug & device makers
Across 79 payments — averaging $54.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Microvention, Inc.$1K
- AbbVie$525
- UCB, Inc.$213
- Argenx US, Inc.$70
- Lilly USA, LLC$37
- plus $203 from 8 others
What the payments were for
- Travel & lodging$2,01347%
- Food & beverage$2,27053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 8 | $1,820 |
| Microvention, Inc. | 12 | $1,415 |
| AbbVie | 37 | $525 |
| UCB, Inc. | 8 | $213 |
| Argenx US, Inc. | 3 | $70 |
| Lilly USA, LLC | 2 | $37 |
| CSL Behring | 2 | $34 |
| Stryker | 1 | $33 |
| Lundbeck LLC | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Neurelis, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Imperative Care, Inc | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Penumbra System$1,534
- SOFIA 6F-131CM STR$824
- WEB Aneurysm Embolization System$145
- RED 72$135
- STENT$121
- HEADWAY ADVANCED SOFT$121
- Benchmark$112
How this compares
$4,283 in reported general payments places this provider in the 55th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 14 | $386 |
| Gabapentin | 27 | $267 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $204 |
| Propranolol Hcl | 12 | $141 |
| Donepezil Hcl | 15 | $83 |
Paid to pharmacies, not to this prescriber.
Other neurology in New Orleans
- Bridget BagertNew Orleans$1.4M
- Joseph TarsiaNew Orleans$1.2M
- Angela TraylorNew Orleans$941K
- Brian CopelandNew Orleans$304K
- John EnglandNew Orleans$268K
- Piotr OlejniczakNew Orleans$241K
- Sheryl Martin-SchildNew Orleans$106K
- Aimee AysenneNew Orleans$41K
- Caroline GoldinNew Orleans$38K
- Elizabeth CrabtreeNew Orleans$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.